Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Posted on: Tuesday, 10 March 2009, 07:00 CDT
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
SOURCE Avineuro Pharmaceuticals, Inc.
Source: PR Newswire
Related Articles
- Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
- Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
- Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimer's Disease.
- Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
- Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
- Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
- Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject(TM)
- Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
- Metabasis Comments on Positive Data Reported By Valeant Pharmaceuticals From Pradefovir Mesylate Phase 2 Study
 |
 |
User Comments (0)
RSS Feeds